Reply to Schierwagen et al.: β-Arrestins in liver disease
- 3 November 2020
- journal article
- letter
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 117 (44), 27085-27086
- https://doi.org/10.1073/pnas.2014931117
Abstract
No abstract availableFunding Information
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK 113159)
This publication has 10 references indexed in Scilit:
- β-Arrestin2 is increased in liver fibrosis in humans and rodentsProceedings of the National Academy of Sciences of the United States of America, 2020
- β-arrestin2 deficiency protects against hepatic fibrosis in mice and prevents synthesis of extracellular matrixCell Death & Disease, 2020
- β-Arrestin2 is a critical component of the GPCR–eNOS signalosomeProceedings of the National Academy of Sciences of the United States of America, 2020
- β-arrestin: Dr Jekyll and Mr Hyde in NASH and fibrosisJournal of Hepatology, 2020
- Depletion of β-arrestin 2 protects against CCl4-induced liver injury in miceBiochemical and Biophysical Research Communications, 2020
- β-arrestin2 Inhibits Apoptosis and Liver Inflamation Induced by Ischemia-reperfusion in Mice via AKT and TLR4 PathwayArchives of Medical Research, 2019
- Indispensable role of β-arrestin2 in the protection of remifentanil preconditioning against hepatic ischemic reperfusion injuryScientific Reports, 2019
- β‐Arrestin1 enhances liver fibrosis through autophagy‐mediated Snail signalingThe FASEB Journal, 2018
- MiR-29a and miR-652 Attenuate Liver Fibrosis by Inhibiting the Differentiation of CD4+ T CellsCell Structure and Function, 2017
- Depletion of β‐arrestin2 in hepatic stellate cells reduces cell proliferation via ERK pathwayJournal of Cellular Biochemistry, 2012